TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07760961: Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

Sponsor: Vogenx, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT07760961 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07760961 Rescue Dossier →